Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746681 | 0.78 | — | — | |
| SCHEMBL16559617 | 0.76 | — | — | |
| SCHEMBL19696242 | 0.75 | SLC22A2 (0.46) | SMN1; SMN2SLC22A2SLC47A1 | |
| SCHEMBL19102477 | 0.74 | SLC22A2 (0.33) | SLC22A2SLC47A1 | |
| SCHEMBL24311330 | 0.72 | GRIN2D (0.32) | SLC22A2SLC47A1 | |
| SCHEMBL18545730 | 0.72 | SLC22A2 (0.30) | SLC22A2SLC47A1 | |
| SCHEMBL18898056 | 0.72 | SLC22A2 (0.30) | SLC22A2SLC47A1 | |
| SCHEMBL18545732 | 0.71 | — | — | |
| SCHEMBL18826707 | 0.69 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL25720236 | 0.69 | TRPA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | IDO1, TDO2, IDO2 | SMN1; SMN2 2009/4885SLC22A2 1382/4885SLC47A1 457/4885 |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | SMN1; SMN2 2220/4885SLC22A2 1286/4885SLC47A1 331/4885 |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | SMN1; SMN2 2009/4885SLC22A2 1382/4885SLC47A1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.